{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:19:57Z","timestamp":1783181997843,"version":"3.54.6"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40290-026-00611-3","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T17:15:15Z","timestamp":1780593315000},"page":"275-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimising Formulations for Paediatric Patients with Inherited Metabolic Disorders: The Case Study of Levocarnitine"],"prefix":"10.1007","volume":"40","author":[{"given":"Stephen","family":"Tomlin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"M\u00fchlhausen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8557-1520","authenticated-orcid":false,"given":"Andriy","family":"Krendyukov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anibh Martin","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,4]]},"reference":[{"key":"611_CR1","unstructured":"Inborn Errors of Metabolism Knowledge base (IEMbase). Available at: https:\/\/www.iembase.org. Last accessed Feb 5th, 2026."},{"issue":"2","key":"611_CR2","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.08.021102","volume":"8","author":"D Waters","year":"2018","unstructured":"Waters D, Adeloye D, Woolham D, Wastnedge E, Patel S, Rudan I. Global birth prevalence and mortality from inborn errors of metabolism: a systematic analysis of the evidence. J Glob Health. 2018;8(2):021102.","journal-title":"J Glob Health"},{"issue":"1","key":"611_CR3","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/s41436-018-0022-8","volume":"21","author":"CR Ferreira","year":"2019","unstructured":"Ferreira CR, van Karnebeek CDM, Vockley J, Blau N. A proposed nosology of inborn errors of metabolism. Genet Med. 2019;21(1):102\u20136.","journal-title":"Genet Med"},{"key":"611_CR4","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/340849","volume":"2010","author":"AM Das","year":"2010","unstructured":"Das AM, Steuerwald U, Illsinger S. Inborn errors of energy metabolism associated with myopathies. J Biomed Biotechnol. 2010;2010:340849.","journal-title":"J Biomed Biotechnol"},{"issue":"1","key":"611_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s11154-018-9455-2","volume":"19","author":"G Wilcox","year":"2018","unstructured":"Wilcox G. Impact of pregnancy on inborn errors of metabolism. Rev Endocr Metab Disord. 2018;19(1):13\u201333.","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"611_CR6","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s10545-018-0209-9","volume":"41","author":"J-M Saudubray","year":"2018","unstructured":"Saudubray J-M, Mochel F. The phenotype of adult versus pediatric patients with inborn errors of metabolism. J Inherit Metab Dis. 2018;41(5):753\u20136.","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"611_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/ijns9010006","volume":"9","author":"CR Lef\u00e8vre","year":"2023","unstructured":"Lef\u00e8vre CR, Labarthe F, Dufour D, Moreau C, Faoucher M, Rollier P, et al. Newborn screening of primary carnitine deficiency: an overview of worldwide practices and pitfalls to define an algorithm before expansion of newborn screening in France. Int J Neonatal Screen. 2023;9(1):6.","journal-title":"Int J Neonatal Screen."},{"issue":"3","key":"611_CR8","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bcp.12267","volume":"79","author":"HK Batchelor","year":"2015","unstructured":"Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015;79(3):395\u2013404.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"611_CR9","first-page":"251","volume":"32","author":"KS Valeur","year":"2018","unstructured":"Valeur KS, Holst H, Allegaert K. Excipients in neonatal medicinal products: never prescribed, commonly administered. Pharmaceut Med. 2018;32(4):251\u20138.","journal-title":"Pharmaceut Med."},{"key":"611_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20112688","author":"F O'Brien","year":"2019","unstructured":"O\u2019Brien F, Clapham D, Krysiak K, Batchelor H, Field P, Caivano G, et al. Making medicines baby size: the challenges in bridging the formulation gap in neonatal medicine. Int J Mol Sci. 2019. https:\/\/doi.org\/10.3390\/ijms20112688.","journal-title":"Int J Mol Sci"},{"key":"611_CR11","doi-asserted-by":"publisher","first-page":"5779","DOI":"10.2174\/1381612823666170926122613","volume":"23","author":"K Kogermann","year":"2017","unstructured":"Kogermann K, Lass J, Nellis G, Metsvaht T, Lutsar I. Age-appropriate formulations including pharmaceutical excipients in neonatal medicines. Curr Pharm Des. 2017;23:5779\u201389.","journal-title":"Curr Pharm Des"},{"issue":"2","key":"611_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.ijpharm.2012.05.004","volume":"435","author":"S Salunke","year":"2012","unstructured":"Salunke S, Giacoia G, Tuleu C. The STEP (safety and toxicity of excipients for paediatrics) database. Part 1-A need assessment study. Int J Pharm. 2012;435(2):101\u201311.","journal-title":"Int J Pharm"},{"issue":"5","key":"611_CR13","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/bcpt.12950","volume":"122","author":"KS Valeur","year":"2018","unstructured":"Valeur KS, Hertel SA, Lundstr\u00f8m KE, Holst H. The cumulative daily tolerance levels of potentially toxic excipients ethanol and propylene glycol are commonly exceeded in neonates and infants. Basic Clin Pharmacol Toxicol. 2018;122(5):523\u201330.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"611_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/jp.2017.165","volume":"38","author":"TO Akinmboni","year":"2018","unstructured":"Akinmboni TO, Davis NL, Falck AJ, Bearer CF, Mooney SM. Excipient exposure in very low birth weight preterm neonates. J Perinatol. 2018;38(2):169\u201374.","journal-title":"J Perinatol"},{"issue":"1","key":"611_CR15","doi-asserted-by":"publisher","first-page":"F55","DOI":"10.1136\/archdischild-2016-311959","volume":"103","author":"S Hsieh","year":"2018","unstructured":"Hsieh S, Sapkota A, Wood R, Bearer C, Kapoor S. Neonatal ethanol exposure from ethanol-based hand sanitisers in isolettes. Arch Dis Child Fetal Neonatal Ed. 2018;103(1):F55\u20138.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"key":"611_CR16","unstructured":"Food and Drug Administration (FDA). Drug safety communication: serious health problems seen in premature babies given Kaletra (lopinavir\/ritonavir) oral solution. 2011, Washington DC. Available at: https:\/\/www.fda.gov\/drugs\/drugsafety\/ucm246002.htm."},{"key":"611_CR17","unstructured":"European Medicines Agency. ICH E11A Guideline on pediatric extrapolation (2025). Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-guideline-e11a-pediatric-extrapolation-step-5_en.pdf. Last accessed 5 May 2025."},{"issue":"23-24","key":"611_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.202200222","volume":"22","author":"J Gil-Mart\u00ednez","year":"2022","unstructured":"Gil-Mart\u00ednez J, Bernardo-Seisdedos G, Mato JM, Millet O. The use of pharmacological chaperones in rare diseases caused by reduced protein stability. Proteomics. 2022;22(23\u201324):e2200222.","journal-title":"Proteomics"},{"issue":"1","key":"611_CR19","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/4801","volume":"5","author":"JQ Fan","year":"1999","unstructured":"Fan JQ, Ishii S, Asano N, Suzuki Y. Accelerated transport and maturation of lysosomal alpha-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med. 1999;5(1):112\u20135.","journal-title":"Nat Med"},{"issue":"22","key":"611_CR20","doi-asserted-by":"publisher","first-page":"2534","DOI":"10.2174\/1568026611212220008","volume":"12","author":"J Underhaug","year":"2012","unstructured":"Underhaug J, Aubi O, Martinez A. Phenylalanine hydroxylase misfolding and pharmacological chaperones. Curr Top Med Chem. 2012;12(22):2534\u201345.","journal-title":"Curr Top Med Chem"},{"key":"611_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1486597","volume":"15","author":"J Zhong","year":"2024","unstructured":"Zhong J, Yu X, Lin Z. Safety assessment of sapropterin dihydrochloride: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS). Front Pharmacol. 2024;15:1486597.","journal-title":"Front Pharmacol"},{"issue":"6","key":"611_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1510198","volume":"375","author":"DP Germain","year":"2016","unstructured":"Germain DP, Hughes DA, Nicholls K, Bichet DG, Giugliani R, Wilcox WR, et al. Treatment of Fabry\u2019s disease with the pharmacologic chaperone migalastat. N Engl J Med. 2016;375(6):545\u201355.","journal-title":"N Engl J Med"},{"issue":"4","key":"611_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22041789","volume":"22","author":"J Gil-Mart\u00ednez","year":"2021","unstructured":"Gil-Mart\u00ednez J, Macias I, Unione L, Bernardo-Seisdedos G, Lopitz-Otsoa F, Fernandez-Ramos D, et al. Therapeutic targeting of fumaryl acetoacetate hydrolase in hereditary tyrosinemia type I. Int J Mol Sci. 2021;22(4):1789.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"611_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12824","volume":"48","author":"AM Das","year":"2025","unstructured":"Das AM, Ballhausen D, Haas D, H\u00e4berle J, Hagedorn T, Janson-Mutsaerts C, et al. Diagnosis, treatment, management and monitoring of patients with tyrosinaemia type 1: consensus group recommendations from the German-speaking countries. J Inherit Metab Dis. 2025;48(1):e12824.","journal-title":"J Inherit Metab Dis"},{"issue":"5","key":"611_CR25","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/jimd.12746","volume":"47","author":"S Stern","year":"2024","unstructured":"Stern S, Wang J, Li RJ, Hon YY, Weis SL, Wang YC, et al. Clinical pharmacology considerations for first-in-human clinical trials for enzyme replacement therapy. J Inherit Metab Dis. 2024;47(5):1096\u2013106.","journal-title":"J Inherit Metab Dis"},{"issue":"12","key":"611_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/biom11121775","volume":"11","author":"C Fern\u00e1ndez-Pereira","year":"2021","unstructured":"Fern\u00e1ndez-Pereira C, San Mill\u00e1n-Tejado B, Gallardo-G\u00f3mez M, P\u00e9rez-M\u00e1rquez T, Alves-Villar M, Melc\u00f3n-Crespo C, et al. Therapeutic approaches in lysosomal storage diseases. Biomolecules. 2021;11(12):1775.","journal-title":"Biomolecules"},{"issue":"5","key":"611_CR27","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s11011-025-01619-5","volume":"40","author":"AM Das","year":"2025","unstructured":"Das AM. Urea cycle defects in adulthood: clinical presentation, diagnosis and treatment in genetically encoded hepatic metabolic disorders with a potential for encephalopathy. Metab Brain Dis. 2025;40(5):192.","journal-title":"Metab Brain Dis"},{"key":"611_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/1177392819857089","volume":"13","author":"T Hydery","year":"2019","unstructured":"Hydery T, Coppenrath VA. A comprehensive review of pegvaliase, an enzyme substitution therapy for the treatment of phenylketonuria. Drug Target Insights. 2019;13:1177392819857089.","journal-title":"Drug Target Insights"},{"issue":"4","key":"611_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1080\/17425255.2017.1262843","volume":"13","author":"J De Las Heras","year":"2017","unstructured":"De Las Heras J, Ald\u00e1miz-Echevarr\u00eda L, Mart\u00ednez-Chantar ML, Delgado TC. An update on the use of benzoate, phenylacetate and phenylbutyrate ammonia scavengers for interrogating and modifying liver nitrogen metabolism and its implications in urea cycle disorders and liver disease. Expert Opin Drug Metab Toxicol. 2017;13(4):439\u201348.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"2","key":"611_CR30","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.gene.2013.10.017","volume":"533","author":"GS Ribas","year":"2014","unstructured":"Ribas GS, Vargas CR, Wajner M. L-carnitine supplementation as a potential antioxidant therapy for inherited neurometabolic disorders. Gene. 2014;533(2):469\u201376.","journal-title":"Gene"},{"issue":"10","key":"611_CR31","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1016\/j.bbamcr.2016.01.023","volume":"1863","author":"N Longo","year":"2016","unstructured":"Longo N, Frigeni M, Pasquali M. Carnitine transport and fatty acid oxidation. Biochim Biophys Acta. 2016;1863(10):2422\u201335.","journal-title":"Biochim Biophys Acta"},{"key":"611_CR32","doi-asserted-by":"publisher","first-page":"5680","DOI":"10.2174\/1381612821666150901110341","volume":"21","author":"MA Turner","year":"2015","unstructured":"Turner MA, Shah U. Why are excipients important to neonates? Curr Pharm Des. 2015;21:5680\u20137.","journal-title":"Curr Pharm Des"},{"issue":"7","key":"611_CR33","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1136\/archdischild-2014-307793","volume":"100","author":"G Nellis","year":"2015","unstructured":"Nellis G, Metsvaht T, Varendi H, Toompere K, Lass J, Mesek I, et al. Potentially harmful excipients in neonatal medicines: a pan-European observational study. Arch Dis Child. 2015;100(7):694\u20139 (ESNEE consortium).","journal-title":"Arch Dis Child"},{"issue":"7","key":"611_CR34","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s00431-014-2272-z","volume":"173","author":"A Souza Jr","year":"2014","unstructured":"Souza A Jr, Santos D, Fonseca S, Medeiros M, Batista L, Turner M, et al. Toxic excipients in medications for neonates in Brazil. Eur J Pediatr. 2014;173(7):935\u201345.","journal-title":"Eur J Pediatr"},{"key":"611_CR35","volume":"7","author":"L Cuzzolin","year":"2018","unstructured":"Cuzzolin L. Neonates exposed to excipients: concern about safety. J Pediatr Neonat Individ Med. 2018;7:e070112.","journal-title":"J Pediatr Neonat Individ Med"},{"key":"611_CR36","doi-asserted-by":"publisher","first-page":"1200521","DOI":"10.3389\/fphar.2023.1200521","volume":"14","author":"S Iacobelli","year":"2023","unstructured":"Iacobelli S, Commins M, Lorrain S, Gouyon B, Ramful D, Richard M, et al. Paraben exposure through drugs in the neonatal intensive care unit: a regional cohort study. Front Pharmacol. 2023;14:1200521.","journal-title":"Front Pharmacol"},{"key":"611_CR37","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.mce.2018.03.014","volume":"474","author":"K Nowak","year":"2018","unstructured":"Nowak K, Ratajczak-Wrona W, G\u00f3rska M, Jab\u0142o\u0144ska E. Parabens and their effects on the endocrine system. Mol Cell Endocrinol. 2018;474:238\u201351.","journal-title":"Mol Cell Endocrinol"},{"key":"611_CR38","doi-asserted-by":"crossref","unstructured":"Binson G, Cariot A, Venisse N, Di Maio M, Rabouan S, Beuzit K, et al. Exposition des nouveau-n\u00e9s aux parab\u00e8nes via les m\u00e9dicaments administr\u00e9s durant leur hospitalisation [Neonates exposure to parabens through medicines administered to inpatients]. Ann Pharm Fr. 2020;78(4):343-50. French.","DOI":"10.1016\/j.pharma.2020.01.005"},{"key":"611_CR39","unstructured":"European Medicines Agency. Reflection paper on the use of methyl-and propylparaben as excipients in human medicinal products for oral use. 2015. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-use-methyl-and-propylparaben-excipients-human-medicinal-products-oral-use_en.pdf. Last accessed 5 May 2025."},{"issue":"5","key":"611_CR40","first-page":"558","volume":"45","author":"S Ullah","year":"2016","unstructured":"Ullah S, Rahman K, Hedayati M. Hyperbilirubinemia in neonates: types, causes, clinical examinations, preventive measures and treatments: a narrative review article. Iran J Public Health. 2016;45(5):558\u201368.","journal-title":"Iran J Public Health"},{"issue":"5","key":"611_CR41","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1002\/phar.1929","volume":"37","author":"S Prabhakaran","year":"2017","unstructured":"Prabhakaran S, Abu-Hasan M, Hendeles L. Benzalkonium chloride: a broncho-constricting preservative in continuous albuterol nebulizer solutions. Pharmacotherapy. 2017;37(5):607\u201310.","journal-title":"Pharmacotherapy"},{"issue":"18","key":"611_CR42","doi-asserted-by":"publisher","first-page":"3307","DOI":"10.1016\/j.cell.2022.07.016","volume":"185","author":"J Suez","year":"2022","unstructured":"Suez J, Cohen Y, Vald\u00e9s-Mas R, Mor U, Dori-Bachash M, Federici S, et al. Personalized microbiome-driven effects of non-nutritive sweeteners on human glucose tolerance. Cell. 2022;185(18):3307-28.e19.","journal-title":"Cell"},{"key":"611_CR43","first-page":"330","volume-title":"Inborn metabolic diseases","author":"b Steinman","year":"2022","unstructured":"Steinman b, Santer R. Disorders of fructose metabolism. In: Saudubray J-M, Baumgartner MR, Garc\u00eda Cazorla A, Walter JH, editors. Inborn metabolic diseases. 7th edition. Berlin: Springer-Verlag GmbH; 2022. p. 330\u20132.","edition":"7th edition"},{"issue":"2","key":"611_CR44","doi-asserted-by":"publisher","first-page":"179","DOI":"10.7326\/0003-4819-105-2-179","volume":"105","author":"NH Shear","year":"1986","unstructured":"Shear NH, Spielberg SP, Grant DM, Tang BK, Kalow W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 1986;105(2):179\u201384.","journal-title":"Ann Intern Med"},{"key":"611_CR45","unstructured":"European Medicines Agency. Propylene glycol used as an excipient. 9 October 2017 EMA\/CHMP\/334655\/2013. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/report\/propylene-glycol-used-excipient-report-published-support-questions-and-answers-propylene-glycol-used-excipient-medicinal-products-human-use_en.pdf."},{"issue":"2","key":"611_CR46","first-page":"188","volume":"29","author":"E Chung","year":"2024","unstructured":"Chung E, Reinaker K, Meyers R. Ethanol content of medications and its effect on blood alcohol concentration in pediatric patients. J Pediatr Pharmacol Ther. 2024;29(2):188\u201394.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"611_CR47","unstructured":"European Medicines Agency. Information for the package leaflet regarding 4 polysorbates used as excipients in medicinal products for 5 human use. 19 November 2018 EMA\/CHMP\/190743\/2016. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/draft-information-package-leaflet-regarding-polysorbates-used-excipients-medicinal-products-human-use_en.pdf."},{"issue":"3","key":"611_CR48","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/jimd.12475","volume":"45","author":"LL Crefcoeur","year":"2022","unstructured":"Crefcoeur LL, Visser G, Ferdinandusse S, Wijburg FA, Langeveld M, Sjouke B. Clinical characteristics of primary carnitine deficiency: a structured review using a case-by-case approach. J Inherit Metab Dis. 2022;45(3):386\u2013405.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"611_CR49","volume":"2012","author":"M Nasser","year":"2012","unstructured":"Nasser M, Javaheri H, Fedorowicz Z, Noorani Z. Carnitine supplementation for inborn errors of metabolism. Cochrane Database Syst Rev. 2012;2012(2):CD006659.","journal-title":"Cochrane Database Syst Rev"},{"key":"611_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-68","volume":"7","author":"PL Magoulas","year":"2012","unstructured":"Magoulas PL, El-Hattab AW. Systemic primary carnitine deficiency: an overview of clinical manifestations, diagnosis, and management. Orphanet J Rare Dis. 2012;7:68.","journal-title":"Orphanet J Rare Dis"},{"key":"611_CR51","doi-asserted-by":"publisher","DOI":"10.4172\/2161-0495.1000e113","volume":"2","author":"K Allegaert","year":"2012","unstructured":"Allegaert K. Propylene glycol in neonates: never prescribed, frequently administered, hardly evaluated. J Clin Toxicol. 2012;2:9.","journal-title":"J Clin Toxicol"},{"issue":"1","key":"611_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13104-019-4486-7","volume":"12","author":"R Soremekun","year":"2019","unstructured":"Soremekun R, Ogbuefi I, Aderemi-Williams R. Prevalence of ethanol and other potentially harmful excipients in pediatric oral medicines: survey of community pharmacies in a Nigerian city. BMC Res Notes. 2019;12(1):460.","journal-title":"BMC Res Notes"},{"issue":"4","key":"611_CR53","first-page":"277","volume":"19","author":"TY Lim","year":"2014","unstructured":"Lim TY, Poole RL, Pageler NM. Propylene glycol toxicity in children. J Pediatr Pharmacol Ther. 2014;19(4):277\u201382.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"3","key":"611_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13030387","volume":"13","author":"K Rouaz","year":"2021","unstructured":"Rouaz K, Chiclana-Rodr\u00edguez B, Nardi-Ricart A, Su\u00f1\u00e9-Pou M, Mercad\u00e9-Frutos D, Su\u00f1\u00e9-Negre JM, et al. Excipients in the paediatric population: a review. Pharmaceutics. 2021;13(3):387.","journal-title":"Pharmaceutics"},{"issue":"3","key":"611_CR55","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40272-016-0173-5","volume":"18","author":"G Nellis","year":"2016","unstructured":"Nellis G, Metsvaht T, Varendi H, Lass J, Duncan J, Nunn AJ, et al. Product substitution as a way forward in avoiding potentially harmful excipients in neonates. Paediatr Drugs. 2016;18(3):221\u201330.","journal-title":"Paediatr Drugs"},{"issue":"1-2","key":"611_CR56","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.ijpharm.2015.06.016","volume":"492","author":"S Salunke","year":"2015","unstructured":"Salunke S, Tuleu C, European Paediatric Formulation Initiative (EuPFI). The STEP database through the end-users eyes\u2212usability study. Int J Pharm. 2015;492(1\u20132):316\u201331.","journal-title":"Int J Pharm"},{"key":"611_CR57","volume":"64","author":"KS Valeur","year":"2017","unstructured":"Valeur KS, Hertel SA, Lundstrom KE, Holst H. Safe excipient exposure in neonates and small children\u2014protocol for the SEEN project. Dan Med J. 2017;64:A5324.","journal-title":"Dan Med J"},{"key":"611_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2024.114447","volume":"203","author":"A Agrawal","year":"2024","unstructured":"Agrawal A, Salunke S, Rumondor A, Thompson K, Caivano G, Walsh J, et al. International Consortium (IQ) for Innovation and Quality in Pharmaceutical Development and European Paediatric Formulation Initiative (EuPFI). Paediatric excipient risk assessment (PERA) tool and application for selecting appropriate excipients for paediatric dosage forms - Part 2. Eur J Pharm Biopharm. 2024;203:114447.","journal-title":"Eur J Pharm Biopharm"},{"key":"611_CR59","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ijpharm.2013.08.064","volume":"457","author":"A Gupta","year":"2013","unstructured":"Gupta A, Khan MA. Challenges of pediatric formulations: a FDA science perspective. Int J Pharm. 2013;457:346\u20138.","journal-title":"Int J Pharm"},{"key":"611_CR60","unstructured":"European Medicines Agency. Annex to the European Commission\u00a0guideline\u00a0on 'Excipients\u00a0in the\u00a0labelling\u00a0and\u00a0package leaflet\u00a0of\u00a0medicinal products\u00a0for human use'. Available at: https:\/\/www.ema.europa.eu\/en\/annex-european-commission-guideline-excipients-labelling-package-leaflet-medicinal-products-human-use#current-version-9397. Last accessed 5 May 2025."},{"key":"611_CR61","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2147\/IJGM.S280330","volume":"13","author":"A Belayneh","year":"2020","unstructured":"Belayneh A, Tadese E, Molla F. Safety and biopharmaceutical challenges of excipients in off-label pediatric formulations. Int J Gen Med. 2020;13:1051\u201366.","journal-title":"Int J Gen Med"},{"issue":"8","key":"611_CR62","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1002\/psp4.12668","volume":"10","author":"SJ McFeely","year":"2021","unstructured":"McFeely SJ, Yu J, Wang Y, Wu C, Ragueneau-Majlessi I. Excipient knowledgebase: development of a comprehensive tool for understanding the disposition and interaction potential of common excipients. CPT Pharmacomet Syst Pharmacol. 2021;10(8):953\u201361.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"483","key":"611_CR63","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau6753","volume":"11","author":"D Reker","year":"2019","unstructured":"Reker D, Blum SM, Steiger C, Anger KE, Sommer JM, Fanikos J, et al. \u201cInactive\u201d ingredients in oral medications. Sci Transl Med. 2019;11(483):eaau6753.","journal-title":"Sci Transl Med"}],"container-title":["Pharmaceutical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00611-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40290-026-00611-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40290-026-00611-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T16:01:54Z","timestamp":1783180914000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40290-026-00611-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,4]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["611"],"URL":"https:\/\/doi.org\/10.1007\/s40290-026-00611-3","relation":{},"ISSN":["1178-2595","1179-1993"],"issn-type":[{"value":"1178-2595","type":"print"},{"value":"1179-1993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,4]]},"assertion":[{"value":"16 April 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 June 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the publication of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"AK is employee of Aspire Pharma Ltd. CM is consultant to Aspire Pharma Ltd and receives travel grant in attending meetings form Takeda Pharma Vertrieb GmbH and Danone Nutricia Metabolics GmbH. Aspire Pharma Ltd manufactures a levocarnitine paediatric oral solution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed equally to conceptualising and drafting the manuscript; all authors critically reviewed the manuscript. All authors read and approved the final version of the manuscript and agree to be accountable for the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}